TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02108236

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: Zhong-wan (RN12), Liang-men (ST21), Shui-fen (RN9) and Qi-hai (RN6) and bilateral acupuncture points Dai-mai (GB26), Tian-shu (ST25), Zu-sanli (ST36), Feng-long(ST40) and Liang-qiu(ST34) will be applied through the skin by acupuncture for 30 minutes every time. Electro-acupuncture apparatus will be connected to both Dai-mai, Zu-sanli and Feng-long, Zhong-wan and Qi-hai for 30 minutes with interrupted waves (2/100HZ).
Study: NCT02449070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: 4 mg iv after randomization, 2 mg ic just before ballooning, 2 mg ic just before stenting
Study: NCT01897298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Urban training
Description: Recommendation to walk a minimum of 5 days per week in urban walkable trails appropriate for the patient.
Study: NCT02738372

Intervention type: OTHER
Intervention: Diagnosis/Prognosis
Description: The present study will be a 24 months multi-center, triple-blind, prospective, cohort study which will be carried out between April 2016 and March 2018. Subjects diagnosed of rotator cuff (RC) tendinopathy, adhesive capsulitis (AC), glenohumeral instability, SLAP lesion, and/or acromioclavicular pathology and fulfill the inclusion criteria will be asked for participating in our study. Several questionnaires that will test the influence of different biopsychosocial factors and the presence of Central Sensitization will be administrated to these subjects. The outcomes will be assessed at baseline and 5 follow-ups (after 3, 6, 12, 18 and 24 months, t1-t6).
Study: NCT03183518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial micellar cleanser
Description: Each participant will have the test product applied topically via semi occlusive patch, on-site by a technician.

Intervention type: OTHER
Group type: OTHER
Intervention: Saline Solution: Sodium Chloride (NaCl; 0.9%)
Description: Each participant will have the reference product applied topically via semi occlusive patch, on-site by a technician.
Study: NCT02457845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G207
Description: Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI
Study: NCT03995446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level laser
Description: low level laser emission on specific acupuncture points

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser
Description: Sham laser
Study: NCT03093298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteroscopy with biopsy sampling and mixed meal test
Description: Enteroscopies with biopsy retrieval and mixed meal tests with blood sampling before and after Roux-en-Y gastric bypass surgery
Study: NCT00666068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: corticotropin releasing hormone (CRH)
Description: 50 µg injected at 2200, 2300, 0000, and 0100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: injected at 2200, 2300, 0000, and 0100

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: injected at 2200, 2300, 0000, and 0100
Study: NCT00687011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron and Dexamethasone
Description: 0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent, plus single IV dose of dexamethasone 8 mg administered 15 minutes before chemotherapy (in the event of a shortage of IV dexamethasone, a single oral dose of dexamethasone 20 mg or a single IV dose of methylprednisolone 125 mg could be administered).
Study: NCT03268577

Intervention type: OTHER
Intervention: Internet-Based Intervention
Description: Complete ASA24

Intervention type: OTHER
Intervention: Internet-Based Intervention
Description: Complete ACT24 reporting

Intervention type: DEVICE
Intervention: Monitoring Device
Description: Wear accelerometer and inclinometer physical activity monitors

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04257136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBI-S
Description: VBI-S is made of small particles of specific lipid called micelles and liposomes for the treatment of hypotension.
Study: NCT00644475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imidapril
Description: tablets; 5, 10, 15, 20 mg; od; 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Description: tablets; 8, 16, 24, and 32 mg; od; 12 weeks
Study: NCT00592241

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Adi Insulin Pump Usability
Description: no intervention
Study: NCT04781439

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IV-to-PO conversion of antibiotics
Description: IV-to-PO switching of antibiotics treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IV-to-PO conversion of antibiotics
Description: IV-to-PO switching of antibiotics treatment
Study: NCT01215552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-0712
Description: A range of single oral dose levels will be explored, utilizing 5mg and 25mg strength capsules
Study: NCT00393484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablets, Oral, 0.5 mg, once daily (0-96 weeks) and (96-240 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine Placebo
Description: Capsules, Oral, 0 mg, once daily (0-96 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Capsules, Oral, 100 mg, once daily (0-96 weeks)~Tablets, Oral, 100 mg, once daily (96-240 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir Placebo
Description: Tablets, Oral, 0 mg, once daily (0-96 weeks)
Study: NCT01764464

Intervention type: DRUG
Group type: OTHER
Intervention: Gralise®
Description: 14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).

Intervention type: DRUG
Group type: OTHER
Intervention: Gralise®
Description: 14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: 14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: 14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).
Study: NCT02462499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inspra (eplerenone)
Study: NCT00001277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-Dotatate
Description: 68Ga-Dotatate PET/CT will be administered prior to a PET/CT scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DOPA
Description: 18F-DOPA PET/CT will be administered prior to a whole-body scan to detect known and occult primary and metastatic bronchial, gastrointestinal and pancreatic neuroendocrine tumors.
Study: NCT01069471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella vaccine
Description: Two intramuscular injections of bioconjugate vaccine will be administrated at D0 and D60.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella vaccine
Description: Two intramuscular injections of bioconjugate vaccine will be administrated at D0 and D60.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella vaccine
Description: Two intramuscular injections of bioconjugate vaccine will be administrated at D0 and D60.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella vaccine
Description: Two intramuscular injections of bioconjugate vaccine will be administrated at D0 and D60.
Study: NCT02400099

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-protein low calorie diet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control low calorie diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anthropometrical measurements

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anthropometrical measurements

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Body composition

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body composition

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 8-h metabolic profile

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 8-h metabolic profile

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Liver biopsy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liver biopsy
Study: NCT00715494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive, physical, and functional rehabilitation
Description: A multicomponent program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients in their home environments over a focused 12 week period with the aid of tele-technology to utilize the expertise of physical therapy, occupational therapy, and neuropsychology.
Study: NCT01563380

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: PRP ready to be injected was supplied in a syringe in a quantity of 8 ml for each knee. The entire procedure was done under complete aseptic precautions. The calcium chloride required for activation was given in a separate syringe in a ratio of 4:1. About 12-16 ml of platelet rich plasma was obtained by this method and it was used for application. To confirm sterility, culture and sensitivity of PRP was performed. Patient's peripheral blood platelet count and the prepared platelet concentrate's platelet count was performed and recorded. Number of tramadol injections given was also noted
Study: NCT01094613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delayed Release 6 mercaptopurine
Description: Delayed Release oral tablet for ileal drug delivery, 80 mg, once nightly before bedtime, for 12 weeks.~Since the study drug must be blinded, patients randomized to this arm will receive the following: 80 mg DR-6MP: 2 active 40 mg DR-6MP tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 Mercaptopurine
Description: Oral tablet(s) to be administered once daily in the AM, for 12 weeks.Purinethol is available only as a 50 mg tablet; patients randomized to this arm will receive varying doses (dependent on baseline body weight and AE profile) throughout the study;and study drug to be blinded. Therefore, patients randomized to this arm to receive combination active Purinethol/comparable placebo. For ex: 50 mg Purinethol= 1 active 50 mg tablet, 2 comparable placebo tablets; 100 mg Purinethol = 2 active 50 mg tablets, 1 placebo tablet; 150 mg Purinethol = 3 active 50 mg tablets. Patients receiving 75 mg or 125 mg will receive alternating daily doses of 50 and 100 mg, or 100 and 150 mg, respectively, to arrive at a weekly average dose of 75 mg or 125 mg.
Study: NCT02487927

Intervention type: BEHAVIORAL
Intervention: weaning
Description: T piece

Intervention type: BEHAVIORAL
Intervention: weaning
Description: T piece
Study: NCT04565834

Intervention type: GENETIC
Intervention: Analysis of Single nucleotide polymorphisms in each group.
Description: The 6 single nucleotide polymorphisms (SNPs) determined will then be genotyped according to the Thermofisher Taqman technique ona 480 LightCycler (Roche Applied Science). 10% of the genotypes will be confirmed via Sanger sequencing on a 3500xl Thermofisher sequencer according to the manufacturer's recommendations.

Intervention type: GENETIC
Intervention: Analysis of Single nucleotide polymorphisms in each group.
Description: The 6 single nucleotide polymorphisms (SNPs) determined will then be genotyped according to the Thermofisher Taqman technique ona 480 LightCycler (Roche Applied Science). 10% of the genotypes will be confirmed via Sanger sequencing on a 3500xl Thermofisher sequencer according to the manufacturer's recommendations.
Study: NCT02190578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reveal G4
Description: All subjects tested with the investigational device, Reveal G4, plus with an algorithm of approved assays for HIV.
Study: NCT01982890

Intervention type: OTHER
Intervention: Control
Description: No intervention as this group is simply followed prospectively.
Study: NCT00716924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 600 mg
Study: NCT04177459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health promoting dialogue
Description: Health promoting dialogues based on the salutogenic theory, focusing on resources within and around the individual, and on coping strategies. Seven individual dialogues for each participant, individually adapted due to the fatigue. The intervention is offered in the participants home or at the local hospital, dependent on the participants fatigue and what is preferred.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment / treatment as usual
Description: Follow-up from primary and secondary health care, and from schools.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment / treatment as usual
Description: Follow-up from primary and secondary health care, and from schools.
Study: NCT02617069

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% normal saline injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable loop recorder

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable loop recorder
Study: NCT00614926

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules are administered on the same schedule as active drug: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day in the absence of clinical improvement and dose limiting side effects. Dose is daily, in A.M.
Study: NCT04004117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl citrate solution sublingual
Description: Solution of fentanyl citrate (DIN : 02384124 / 02240434 / 02385406) will be administered sublingually by syringe. The dose is 12,5 mcg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl citrate solution sublingual
Description: Solution of fentanyl citrate (DIN : 02384124 / 02240434 / 02385406) will be administered sublingually by syringe. The dose is 12,5 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral liquid
Description: Placebo will consist in simple syrup (simple syrup B.P. - NPN: 00050121) administered sublingually with syringe.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral liquid
Description: Placebo will consist in simple syrup (simple syrup B.P. - NPN: 00050121) administered sublingually with syringe.
Study: NCT02547766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra is an Interleukin-1 receptor antagonist that will be given to the patient via subcutaneous injection for a period of 14 consecutive days.
Study: NCT01826461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDI-192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDI-192

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study: NCT04674397

Intervention type: RADIATION
Intervention: Radioisotope GFR test
Study: NCT02649543

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vacuum Assisted Closure
Description: A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia is closed with a continuous Polyglycolic Acid 0 suture. The VAC® system is then used, with change of dressings every 48 hrs. The wound is closed using Polypropylene 2-0 only after healthy granulation tissue and no signs of infection are present.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Primary Closure
Description: A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia was closed with a continuous Polyglycolic Acid 0 suture. The wound is left open for at least 7 days, after which closure with Polypropylene 2-0 takes place if considered suitable by a board certified surgeon.
Study: NCT00849251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study: NCT03757780

Intervention type: OTHER
Intervention: Questionaire
Description: A questionaire will be made to pregnant ladies who take caffeine during pregnancy
Study: NCT01913379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDV3100
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDV3100
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDV3100
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral
Study: NCT04768894

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Second transurehral resection of bladder tumour
Description: Remove of the bladder tumour as endoscopically

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Second transurehral resection of bladder tumour
Description: Remove of the bladder tumour as endoscopically

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Second transurehral resection of bladder tumour
Description: Remove of the bladder tumour as endoscopically
Study: NCT02159937

Intervention type: OTHER
Intervention: Blood sampling by vena punction.
Description: In vitro tests will be performed after blood sample collection from metastatic cancer patients
Study: NCT02786719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: CYCLE 1+2 (given by intravenous catheter daily for 5 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: CYCLE 1+2 (given by intravenous catheter daily for 5 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cycle 3+5 (given daily x 4 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Cycle 3+5 (given daily for 3 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Cycle 4+6 (given daily for 3 days)
Study: NCT00849251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV or PO
Study: NCT01354093

Intervention type: DRUG
Intervention: zeaxanthin
Description: 10 mg of EyePromise 10 (zeaxanthin) supplement, taken twice a day

Intervention type: DRUG
Intervention: zeaxanthin
Description: 10 mg of EyePromise 10 (zeaxanthin) supplement, taken once a day
Study: NCT01409096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone
Description: Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and central nervous system.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredient matching the active medication in appearance.
Study: NCT00442702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mircera
Description: Starting dose of 120, 200 and 360 micrograms administered by subcutaneous injection once a month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: As prescribed, subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling specifications.
Study: NCT01952457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver PTX
Study: NCT02786719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cycle 4+6 (given daily for 2 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Cycle 4+6 (given daily for 3 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Granulocyte macrophage colony stimulating factor (rhu GM-CSF, rGM-CSF, GM-CSF)
Study: NCT01430819

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation
Description: 0.5 mL, Intramuscular
Study: NCT00653159

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel-releasing intrauterine device (LNG-IUS)
Description: Teens are randomly assigned to receive the LNG-IUS after completing a screening visit.
Study: NCT01952457

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: prosthetic bypass
Study: NCT03670316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Algorithm Treatment
Description: Varenicline was selected as the first line of treatment for patients willing to take a medication twice per day and wanting cessation. Following varenicline, bupropion and then NRT are subsequent options. In terms of preference for NRT, nicotine patches would be the first option followed by lozenge, gum, inhaler, and nasal spray. The order of NRT within the algorithm is based upon patient familiarity and number of clinical trials supporting their use. Combination NRT (e.g., patch and lozenge) or adding NRT to varenicline or bupropion is offered to participants who have made an unsuccessful quit attempt with these medications in the past. If none of these medications are appropriate, then the participant is offered counseling only.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quitline only
Description: eTAU participants will complete the same algorithm questions but will not have this information sent to their provider, although their provider may elect to prescribe medication as part of standard of care. Participants will be referred to a quitline for behavioral support services for cessation.